Substanzen · Cathinon-Derivate
Eutylone (bk-EBDB)
- Bevorzugter Name
- Eutylone (bk-EBDB)
- IUPAC-Name
- 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one
- CAS-Nummer der Stammverbindung (Referenz)
- 802855-66-9
- Summenformel
- C13H17NO3
- Molekulargewicht
- 235.28 g/mol
- InChIKey
- YERSNXHEOIYEGX-UHFFFAOYSA-N
- PubChem
- CID 57360686
- Quelle
- PubChem
- Geprüfte Synonyme und Katalogkürzel
-
Eutylone bk-EBDB N-Ethylbutylone
Passende Artikel im aktuellen Shop-Katalog
Geprüftes Pharmakologie- & Toxikologie-Dossier
Eutylone (bk-EBDB / N-Ethylbutylone)
Rezeptor-Telemetrie & Wirkmechanismus
Hybrid monoamine transporter compound (Glatfelter et al., 2021; WHO 44th ECDD): acts as an uptake blocker at DAT (rat IC50 = 120 ± 10 nM; human hDAT IC50 = 281 ± 80 nM) and NET (rat IC50 = 1,280 ± 140 nM; human hNET IC50 = 700 ± 100 nM), while acting as a weak partial substrate releaser at SERT reaching only 50% of maximal response (human hSERT IC50 = 640 ± 160 nM). This explains why eutylone yields a modest, short-lived MDMA-like warm glow followed by hours of pure dopaminergic/adrenergic stimulation.
Biotransformation & Active Metabolites
Metabolized via beta-ketone reduction, CYP2D6/CYP2C19-catalyzed demethylenation of the benzodioxole ring, COMT O-methylation, and Phase II conjugation. Also promotes antidiuretic hormone (ADH) release, causing temporary urinary difficulty and hyponatremia risk if excess water is consumed.
Zeitliche Pharmakokinetik
Energetic, sociable cathinone combining a brief, mild entactogenic body tingle and conversational openness with a long, insistent catecholaminergic stimulant tail.
- Onset 15–45 minutes oral (5–15 minutes mucosal exposure)
- Peak Window 1–2 hours oral (30–60 minutes mucosal exposure)
- Total Window 4–8 hours oral (DEA reports effects lasting up to 8 hours; mucosal exposure primary phase 1.5–3 hours)
- Residual / Half-Life 2–24 hours of persistent wakefulness, insomnia, and fatigue; in vivo human elimination half-life is unverified.
Major repeated exposure trap: eutylone's mild empathogenic glow fades rapidly because SERT release caps at 50% maximal efficacy. 'Piggy-backing' extra doses to chase a stronger MDMA-like roll stacks long-lasting DAT/NET blockade—causing up to 8–24 hours of sleeplessness, agitation, tachycardia, rhabdomyolysis, seizures, and documented single-use fatalities as amounts approach or exceed 200 mg.
Quantitatives Wirkungsspektrum (Literaturdaten)
Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.
35 mg
Subtle wakefulness, light mood lift, and mild conversational ease.
Slight dry mouth and gentle increase in pulse.
40–60 mg
Sociable energy, talkativeness, modest emotional warmth, and music enhancement.
Moderate heart-rate rise, light sweating, and appetite suppression.
60–100 mg (WHO forum reports up to 100–200 mg oral; ~50 mg mucosal exposure)
Clear elevated dopaminergic tone, social disinhibition, warm tactile tingling transitioning into alert dopaminergic stimulation.
Elevated heart rate and blood pressure, dry mouth, moderate jaw tension, and ADH-mediated difficulty urinating.
100–180 mg
Forced physical restlessness, vibrating vision (nystagmus), hand unsteadiness, anxiety on offset, and persistent inability to sleep.
Strong tachycardia, hypertension, bruxism, hyperthermia in hot environments, and water-intoxication risk if over-drinking.
180–200+ mg (counterfeit street tablets seized at 300–350 mg linked to severe poisonings)
Acute panic, paranoia, visual hallucinations, agitated delirium, and stimulant psychosis.
Severe hyperthermia, rhabdomyolysis, hypertension, tonic-clonic seizures, and documented fatal intoxication.
Wechselwirkungsmatrix — Niemals kombinieren
Lebensgefahr — Niemals kombinieren
Partial SERT release plus DAT/NET blockade under MAO inhibition triggers fatal serotonin syndrome, hyperpyrexia, and hypertensive crisis.
Synergistic serotonergic and adrenergic overload precipitates hyperthermia, seizures, rhabdomyolysis, and serotonin toxicity.
Opioid co-ingestions account for fatal eutylone overdoses; co-stimulants cause severe hypertension, vasoconstriction, and seizures.
Hohes Risiko — Vermeiden
Eutylone promotes ADH release (urinary retention); chugging excessive water causes dangerous water intoxication (hyponatremia), while alcohol worsens overheating and cardiac strain.
Impairs hepatic demethylenation of eutylone, prolonging cardiovascular stimulation and insomnia.
Vorsicht / Abschwächung
Blunts eutylone's already modest partial SERT warmth while leaving long-lasting adrenergic wakefulness intact.
Can heighten heart rate and trigger anxious thought loops during eutylone's protracted offset.
Isomeren- & Strukturvergleich
Compared to 4-MMC and 3-MMC (full monoamine releasers), eutylone is a hybrid DAT/NET blocker and only a 50%-efficacy partial SERT releaser: its warm 'rolly' phase is noticeably milder and shorter than 4-MMC, while its wakeful stimulant tail lasts longer (up to 8 hours). Compared to MDPHP (which also has a 3,4-methylenedioxy ring), eutylone is ~3-fold gentler per milligram (common 60–100 mg vs. 20–35 mg) and retains mild serotonergic warmth that MDPHP lacks.
Stabilität & Lagerung
Form: Odorless crystalline solid or crystals as the hydrochloride salt. · Soluble in water, methanol, and ethanol as the hydrochloride salt.
High analytical stability due to the 3,4-methylenedioxy group (blood sample t1/2 of 31 days at 20 °C in vitro); store dry and protected from light.
Cross-Tolerance & Dependence Profile
Cross-tolerant with all dopaminergic and serotonergic stimulants (4-MMC, 3-MMC, MDMA, NEP); tolerance halves in 3–7 days and resets in 1–2 weeks. High risk of compulsive 'piggy-back' repeated exposure; withdrawal after heavy use involves ~1 week of exhaustion, headaches, tremors, sweating, and low mood.
Chemische Struktur und Molekülprofil
Eutylone (bk-EBDB) (1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one) ist eine Referenzverbindung aus der Stoffklasse Cathinon-Derivate mit der Summenformel C13H17NO3 und einer molaren Masse von 235.28 g/mol. Die Stammverbindung wird unter der CAS-Nummer 802855-66-9 sowie in der NCBI-PubChem-Datenbank unter CID 57360686 geführt (Standard-InChIKey: YERSNXHEOIYEGX-UHFFFAOYSA-N).
Quellen
- PubChem — PubChem (2026-11-12)
Referenztoxikologie und Sicherheitsprofil
Laut dokumentierten Referenzdaten (PubChem / PsychonautWiki, CC BY 4.0) gehört Eutylone (bk-EBDB) zur chemischen Klasse Cathinon-Derivate. Als substituiertes Beta-Keton (Cathinon-Derivat) erfordert diese Verbindung eine präzise analytische Reinheitsprüfung; Kontraindikationen bestehen insbesondere mit MAO-Hemmern und Serotonergika. Beim Umgang im Labor sind geeignete persönliche Schutzausrüstung und das Sicherheitsdatenblatt (SDB) zu beachten.
Quellen
- PubChem — PubChem (2026-11-12)
Analytischer Verwendungszweck und Laborhinweis
Dieses Datenblatt dient ausschließlich der chemischen, analytischen und toxikologischen Dokumentation. Das Material ist nicht für den menschlichen Verzehr bestimmt. Ein Forschungshinweis begründet keinen Rechtsstatus.
Quellen
- Gesetze im Internet — Neue-psychoaktive-Stoffe-Gesetz (NpSG) & BtMG — Bundesministerium der Justiz (2026-11-12)